degarelix
1. Basic Product Identification
Name: Degarelix
Class: GnRH (Gonadotropin-Releasing Hormone) receptor antagonist
ATC Code: L02BX02
Molecular Formula: C₈₂H₁₈₅N₃₃O₁₈
Molecular Weight: ~1632 g/mol
Type: Synthetic decapeptide derivative
Appearance: White to off-white lyophilized powder
Dosage Form: Sterile injectable (subcutaneous)
2. Therapeutic Knowledge
Indication:
Advanced prostate cancer (hormone-dependent)
Therapeutic class:
Androgen deprivation therapy (ADT)
Clinical role:
Rapid testosterone suppression without flare effect
???? Key advantage: avoids testosterone surge seen with GnRH agonists
3. Mechanism of Action (MOA)
Directly blocks GnRH receptors in pituitary gland
Rapid suppression of:
LH (Luteinizing Hormone)
FSH (Follicle Stimulating Hormone)
Leads to:
↓ Testosterone production in testes
Key advantage:
No initial testosterone flare (unlike leuprolide/goserelin)
4. Pharmacokinetics (ADME)
Absorption
Subcutaneous injection → depot formation
Slow release into systemic circulation
Distribution
Peptide with limited tissue penetration
High receptor specificity
Metabolism
Peptidic degradation via proteolysis (not CYP mediated)
Excretion
Mainly via hepatic/biliary breakdown and renal excretion of fragments
Half-life
Long duration due to depot formulation (dose dependent)
5. Dosage & Administration
Standard regimen
Initial dose: 240 mg (split into two 120 mg injections)
Maintenance dose: 80 mg monthly
Route
Subcutaneous injection (abdomen preferred)
Administration notes
Must be reconstituted before injection
Avoid IV administration (strictly SC only)
6. Formulation Knowledge
Dosage form
Sterile lyophilized powder for injection
Key formulation components
Degarelix acetate
Mannitol (bulking agent)
Sterile water for injection (reconstitution)
Special formulation system:
Self-assembling peptide depot system
Forms gel-like depot after injection
7. Raw Materials Knowledge
API: Degarelix acetate (peptide synthesis product)
Key raw inputs:
Protected amino acids
Solid-phase peptide synthesis resins
Coupling reagents (HBTU, DCC, etc.)
Critical requirement:
Ultra-high peptide purity (>98%)
8. Manufacturing Process Knowledge
API manufacturing (high-level)
Solid Phase Peptide Synthesis (SPPS)
Stepwise amino acid coupling
Cleavage from resin
Purification via preparative HPLC
Lyophilization
Formulation process
Sterile compounding
Lyophilization cycle development
Aseptic filling into vials
Nitrogen purging
Critical challenges:
Peptide aggregation control
Sterility assurance level (SAL)
Impurity control (deletion sequences)
9. Analytical & QC Knowledge
Key tests:
Assay (RP-HPLC)
Peptide purity profiling
Related substances (deletion sequences)
Water content (Karl Fischer)
Sterility testing
Endotoxin (LAL test)
Particulate matter (visible & sub-visible)
Critical impurities:
Truncated peptides
Deamidation products
Oxidized methionine residues
10. Regulatory Knowledge
Approved by FDA & EMA
Product type:
Sterile injectable biologic-like peptide drug
Requires:
Full CMC documentation
Sterile manufacturing compliance (EU Annex 1, FDA aseptic guidance)
Strict controls:
Cold chain validation
Aseptic processing validation
11. Storage & Stability
Store at 2–8°C (refrigerated)
Protect from:
Heat
Light
After reconstitution:
Must be used immediately
Stability concerns:
Peptide degradation (hydrolysis, oxidation)
12. Packaging Knowledge
Primary packaging:
Type I glass vials
Secondary packaging:
Protective cartons with cold chain insulation
Shipment:
Cold chain (2–8°C)
Temperature monitoring devices (data loggers)
13. Safety & Toxicology
Common adverse effects:
Hot flashes
Injection site reactions
Fatigue
Serious risks:
QT prolongation (rare)
Liver enzyme elevation
Hormonal effects:
Testosterone suppression
Contraindications:
Hypersensitivity to peptide components
14. Market & Commercial Knowledge
Market segment:
Oncology (prostate cancer therapy)
Key competitor:
Leuprolide (GnRH agonist)
Goserelin
Triptorelin
Key brand:
Firmagon
Market drivers:
Rising prostate cancer incidence
Preference for rapid testosterone suppression therapies
15. Intellectual Property (IP)
Original developer: Ferring Pharmaceuticals
Strong peptide formulation patents:
Depot formation technology
Injection system design
IP barriers:
Manufacturing process complexity
Sterile formulation know-how
16. Environmental & EHS Knowledge
Peptide manufacturing requires:
Controlled waste streams (organic solvents)
Bioactive waste disposal protocols
EHS concerns:
Aseptic cleanroom safety
Cold storage energy consumption
Low environmental toxicity post-use
17. Export Documentation Knowledge
COA (Certificate of Analysis)
GMP certificate (sterile manufacturing)
Cold chain validation reports
Stability data (ICH Zone IV important for export markets)
Sterility assurance documentation
Endotoxin compliance reports
18. Business Development Knowledge
High-value oncology injectable market
Key regions:
USA, EU, Japan
Emerging oncology markets (India, China)
Strategy:
Biosimilar/complex generic entry barriers
Hospital tender participation
Cold chain distribution partnerships
19. Advanced Technical Knowledge
Peptide self-assembly into depot gel is key innovation
Requires precise pH and ionic strength control
Lyophilization cycle optimization critical for stability
Protein aggregation risk Belgium management
20. AI & Digital Knowledge (Modern Pharma)
AI applications:
Peptide folding & aggregation prediction
Lyophilization cycle optimization
Stability prediction modeling
Digital QA:
Real-time environmental monitoring in cleanrooms
Cold chain IoT tracking systems
Smart manufacturing:
PAT tools for peptide purity monitoring
21. Sales Team Product Knowledge Checklist
Sales teams must understand:
Mechanism: GnRH antagonist (no flare effect)
Indication: prostate cancer only
Advantage vs agonists:
Faster testosterone suppression
Administration:
Injection schedule importance
Objections:
“Why injections monthly?” → depot system explanation
“Side effects?” → hormonal suppression expected
22. Most Important Technical Documents
Sterile CMC dossier
Lyophilization cycle validation reports
Aseptic process validation
Stability reports (ICH long-term + accelerated)
Peptide impurity profile
Endotoxin validation reports
Cold chain validation reports
Device/injection system validation
23. Ultimate Pharma Product Mastery Summary
Degarelix is:
A highly complex synthetic peptide oncology drug
Used for rapid androgen deprivation in prostate cancer
Technically challenging due to:
Peptide synthesis complexity
Sterile lyophilized formulation
Cold chain dependency
???? Competitive success depends on:
Peptide purity excellence
Sterile manufacturing capability
Cold chain logistics strength
Regulatory compliance in injectables